Journalartikel

Frequent epigenetic inactivation of RASSF10 in thyroid cancer


AutorenlisteSchagdarsurengin, U; Richter, AM; Wöhler, C; Dammann, RH

Jahr der Veröffentlichung2009

Seiten571-576

ZeitschriftEpigenetics

Bandnummer4

Heftnummer8

ISSN1559-2294

eISSN1559-2308

Open Access StatusBronze

DOI Linkhttps://doi.org/10.4161/epi.4.8.10056

VerlagTaylor and Francis Group


Abstract

The Ras association domain family (RASS F) encodes for distinct tumor suppressors and several members are frequently silenced in human cancer. In our study, we analyzed the role of a novel RASS F member termed RASS F10 in thyroid carcinogenesis. The RASSF10 CpG island promoter was intensively methylated in nine thyroid cancer cell lines and in 66% of primary thyroid carcinomas. RASSF10 methylation was significantly increased in primary thyroid carcinoma compared to normal thyroid and follicular adenoma (0 and 10%, respectively; p < 0.004). Patients with cancerous lymph nodes were significantly hypermethylated for RASSF10 in primary thyroid tumors compared to those with non-affected lymph nodes (79 vs. 36%; p = 0.047). RASSF10 promoter hypermethylation correlated with a reduced expression and treatment with a DNA methylation inhibitor reactivated RASSF10 transcription. In summary, our data show frequent epigenetic inactivation of RASSF10 in thyroid cancer. These results suggest that RASSF10 may encode a novel epigenetically inactivated candidate tumor suppressor gene in thyroid carcinogenesis.




Zitierstile

Harvard-ZitierstilSchagdarsurengin, U., Richter, A., Wöhler, C. and Dammann, R. (2009) Frequent epigenetic inactivation of RASSF10 in thyroid cancer, Epigenetics, 4(8), pp. 571-576. https://doi.org/10.4161/epi.4.8.10056

APA-ZitierstilSchagdarsurengin, U., Richter, A., Wöhler, C., & Dammann, R. (2009). Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics. 4(8), 571-576. https://doi.org/10.4161/epi.4.8.10056



Nachhaltigkeitsbezüge


Zuletzt aktualisiert 2025-10-06 um 09:53